CD11b-deficiency diminished AF vulnerability and preserved conduction velocity following angiotensin II treatment.

(A, B) Number and total time of AF-episodes during an electrophysiological stimulation procedure in WT and CD11b^−/− mice upon vehicle or Ang II application. *  =  p<0.05. (C) Example electrical tracings of surface and intracardiac leads from Ang II treated WT and CD11b^−/− mice during electrophysiological burst stimulation with cycle length of 20 ms. (D) Electrical conduction velocity in propagation direction as assessed by epicardial mapping of Langendorff-perfused hearts of WT and CD11b^−/− mice. ***  =  p<0.001. (E) Representative examples of conduction properties of epicardial activation mapping.